Why Expanded Access Programs Often Originate in Medical Affairs

Expanded Access Programs (EAPs)—also known as compassionate use—play a critical role in bridging the gap between clinical development and patient need. They provide patients with serious or life-threatening conditions access to investigational therapies outside of clinical trials, often when no comparable alternatives exist.

Across the pharmaceutical and life sciences industry, a consistent pattern has emerged: Expanded Access Programs frequently originate within Medical Affairs. This is not incidental—it reflects the unique position Medical Affairs holds at the intersection of science, ethics, patient need, and external engagement.

At MedaSystems, we’ve observed this dynamic across organizations of all sizes. Here’s why Medical Affairs is often the natural home—and origin point—for Expanded Access. At a recent conference in Denver, MAPS Americas, this perspective was shared by many in the medical affairs community and those organizations who provide important technology and services.

1. Patient-Centric Mandate

Medical Affairs is fundamentally oriented around patient outcomes and unmet medical needs. Unlike Commercial teams, which focus on approved products and market strategy, or Clinical Development, which focuses on regulatory endpoints, Medical Affairs is tasked with understanding real-world patient challenges.

Expanded Access requests typically arise when:

• Patients are ineligible for clinical trials

• Disease progression outpaces development timelines

• No approved therapies remain

These scenarios demand a patient-first mindset. Medical Affairs is structurally and culturally aligned to evaluate such cases through a scientific and ethical lens, making them the logical initiators of EAPs.

2. Scientific and Clinical Expertise

EAPs require careful evaluation of benefit-risk profiles outside the controlled environment of a clinical trial. This includes:

• Reviewing available clinical and preclinical data

• Assessing safety signals

• Determining appropriate dosing and monitoring

Medical Affairs teams are staffed with physicians, scientists, and therapeutic experts who can interpret evolving data and make informed decisions in complex, individualized situations. This capability is essential when standard protocols don’t apply.

3. External Stakeholder Engagement

Medical Affairs serves as the primary interface with healthcare professionals (HCPs), key opinion leaders (KOLs), and increasingly, patient advocacy groups. These stakeholders are often the source of Expanded Access requests.

Because Medical Affairs already:

• Maintains trusted relationships with physicians

• Understands real-world treatment landscapes

• Engages in scientific exchange (not promotion)

…it is best positioned to receive, triage, and respond to EAP inquiries in a compliant and credible way.

4. Compliance and Ethical Governance

Expanded Access sits in a highly sensitive regulatory and ethical space. Programs must balance:

• Patient need vs. clinical trial integrity

• Fair access vs. limited supply

• Transparency vs. regulatory constraints

Medical Affairs operates independently from Commercial influence and is trained to navigate non-promotional, compliance-driven interactions. This independence is critical to ensuring that EAP decisions are grounded in ethics and science—not market considerations.

5. Cross-Functional Coordination

While Medical Affairs often initiates EAPs, execution requires coordination across multiple functions:

• Clinical Development (data and protocol alignment)

• Regulatory Affairs (health authority engagement)

• Supply Chain (drug availability)

• Legal and Compliance (frameworks and policies)

Medical Affairs frequently acts as the hub connecting these groups. Their holistic view of the product lifecycle allows them to orchestrate the complex workflows required to operationalize an EAP.

6. Insight Generation and Feedback Loop

Expanded Access Programs are not just pathways for treatment—they are also valuable sources of insight. Medical Affairs can capture:

• Real-world safety and tolerability observations

• Physician treatment patterns

• Patient outcomes in broader populations

These insights can inform:

• Future clinical trial design

• Label expansion strategies

• Scientific communication

Because Medical Affairs is already responsible for evidence generation and dissemination, it can integrate EAP learnings into the broader development strategy.

7. Organizational Trust and Neutrality

Internally, Medical Affairs is often viewed as a neutral, science-driven function. This makes it a trusted owner for sensitive decisions such as:

• Who receives access

• Under what conditions

• How exceptions are handled

This neutrality is essential in maintaining credibility—both within the organization and externally with regulators, physicians, and patients.

The MedaSystems Perspective

At MedaSystems, we see Expanded Access as more than a regulatory pathway—it is a reflection of an organization’s commitment to patients. The fact that these programs often originate in Medical Affairs underscores the department’s evolving role as a strategic leader, not just a support function.

As therapies become more complex and patient expectations continue to rise, the importance of Medical Affairs in initiating and shaping Expanded Access will only grow. Organizations that empower Medical Affairs with the right systems, governance, and cross-functional alignment will be better positioned to deliver access responsibly and efficiently.

Expanded Access begins with a question: What can we do for this patient now?
Medical Affairs is uniquely equipped to answer it.